DFDA

Magnesium Sulfate

Treatment for Maternal Hypertensive Disorders

Typical Dosage: 4-6 g IV loading dose, then 1-2 g/hour infusion

Effectiveness
95%
Safety Score
58%
Clinical Trials
1
Participants
20K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
58
DangerousModerateSafe
Treatment Details
Dosage Range
4-6 g IV loading dose, then 1-2 g/hour infusion
Time to Effect
immediate (IV)
Treatment Duration
24 hours post-delivery or post-seizure
Evidence Quality
HIGH
Number Needed to Treat (NNT)
18(Treat 18 patients to see 1 additional successful outcome)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$1,200
Side Effect Mgmt:$0
Total Annual:$1,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
QALYs Gained
0.8
Magnesium Sulfate Outcomes

for Maternal Hypertensive Disorders

Efficacy Outcomes
Overall Effectiveness
+95%
Response Rate
+90%
Common Side Effects
Flushing
+15%
Warmth
+15%
Nausea
+7%
Headache
+7%
Muscle weakness
+5%
Respiratory depression
+0.5%

Sources:

iiste.org
obgproject.com
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
1 completed trial for Magnesium Sulfate in Maternal Hypertensive Disorders

Risk Analysis of Intensive Care Mangement on Maternal and Fetal Outcome of Severe Preeclampsia and Eclampsia

NCT03412552COMPLETED
View Study
1.24K participants
OBSERVATIONAL
Cairo, Egypt
Started: Oct 1, 2015